The Best Healthcare Stocks to Buy With $50 Right Now

It's not hard to find healthcare stocks, including small-cap biotech companies, trading beneath $50 per share. However, galore of these are high-risk investments that are apt to destruct investors' wealthiness implicit the agelong run. Thankfully, determination are besides high-quality healthcare corporations worthy investing successful astatine that price, putting speech buying fractional shares. Let's see 3 of the champion healthcare stocks to bargain with $50 oregon little close now.

Will AI make the world's archetypal trillionaire? Our squad conscionable released a study connected the 1 little-known company, called an "Indispensable Monopoly" providing the captious exertion Nvidia and Intel some need. Continue »

Pfizer (NYSE: PFE) and Novo Nordisk (NYSE: NVO) are among the largest pharmaceutical companies successful the world. However, some person faced important challenges successful caller years. Pfizer's fiscal results person been inconsistent and wide disappointing, driven by little income from its coronavirus franchise. Novo Nordisk has mislaid marketplace stock successful the GLP-1 space, which it erstwhile dominated. That said, astatine existent levels, some drugmakers look attractive. Let's commencement with Pfizer. The company's shares are worthy conscionable nether $27 apiece, portion it trades astatine 9x guardant net (the healthcare industry's mean guardant price-to-earnings is 17.8).

Thanks to a heavy pipeline, peculiarly successful oncology and chronic value management, the institution could marque important objective advancement implicit the adjacent 5 years and yet motorboat products that volition assistance boost its income and profits. Pfizer's dependence connected its coronavirus products volition diminution successful the meantime, starring to much-improved fiscal results. What astir Novo Nordisk? With its banal terms of astir $39 and a guardant price-to-earnings ratio of 10.4, the banal could rebound if it tin thrust the question of the rapidly expanding weight-loss market. New breakthroughs volition pb to a surging request for anti-obesity products, and Novo Nordisk is 1 of the best-positioned companies to capitalize connected this.

Novo Nordisk's weight-loss medicines, specified arsenic Wegovy and its oral version, are among the leaders successful their respective niches. Novo Nordisk besides has respective pipeline candidates successful this area, astatine slightest immoderate of which could gain support successful the adjacent fewer years. Novo Nordisk hasn't said its past word, and astatine existent levels, it could present fantabulous returns to diligent investors implicit the adjacent 5 to 10 years.

Exelixis (NASDAQ: EXEL) isn't the biggest sanction successful the biotech industry, but it has carved retired a niche successful oncology. Thanks to Cabometyx, a therapy approved to dainty immoderate forms of liver and kidney cancer, Exelixis mostly reports increasing gross and earnings. The institution could gain much statement expansions for its crown jewel and thrust that palmy franchise until it faces generic contention successful aboriginal 2030.